|

Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy

RECRUITINGPhase 3Sponsored by Tanta University
Actively Recruiting
PhasePhase 3
SponsorTanta University
Started2025-02-20
Est. completion2026-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06846086

Summary

The aim of current study is to: Evaluate the cardioprotective effects of melatonin in patients with cardiomyopathy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients (≥18 years) with a confirmed diagnosis of cardiomyopathy based on clinical, echocardiographic, or imaging findings. .
* Stable condition on standard cardiomyopathy medications (e.g., ACE inhibitors, beta-blockers).
* Ability to provide informed consent.

Exclusion Criteria:

* Recent hospitalization for cardiomyopathy exacerbation (within the last 3 months).
* Severe kidney or liver impairment.
* Use of other investigational drugs or antioxidants.
* Pregnancy or planning to be pregnant in the next 6 months
* Previous known hypersensitivity to melatonin.
* Presence of atrial fibrillation or other significant arrhythmias at baseline.
* Participation in another research.

Conditions2

CardiomyopathiesHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.